Thermo Fisher's Patheon division has announced an exclusive agreement with Texas-based CDMO AustinPX to install its KinetiSol equipment.
Under the terms of the arrangement, AustinPx will install KinetiSol equipment at Thermo Fisher's oral solid drug manufacturing sites in Bend, Oregon and Cincinnati, Ohio and integrate it into Patheon’s Quadrant 2 AI/ML-driven predictive platform.
This will make Thermo Fisher the exclusive third-party CDMO provider of KinetiSol Formulator technology, offering customers an integrated pathway to advance KinetiSol-enabled products throughout the drug development lifecycle.
KinetiSol is AustinPx's solvent-free, fusion-based technology that creates amorphous solid dispersions (ASD) to improve the bioavailability of poorly soluble drugs.
According to the firm, it enhances scalability and supports environmental and economic sustainability, as well as expanding formulation options for difficult APIs, including those with high melting points, poor solubility in organic solvents and heat sensitivity.
The company said it had seen significant interest in (and utilisation of) KinetiSol among sponsors working with poorly soluble drug candidates that require improved bioavailability, manufacturability and sustainability.
Since its launch in 2022, KinetiSol has been used by more than 70 pharmaceutical and biotech companies, including seven of the top ten large pharmas.
“This agreement marks an important milestone for AustinPx, our clients and the growing number of molecules enabled by KinetiSol Technology,” said Elizabeth Hickman, CEO of AustinPx.
Thermo Fisher’s agreement with KinetiSol provides important external validation from an established global CDMO with deep experience in advanced formulation technologies and commercial manufacturing.
“At Thermo Fisher Scientific, we are committed to helping our customers accelerate the development and delivery of life-changing medicines,” added Jennifer Cannon, President, Commercial, Biopharma Services, Thermo Fisher Scientific.
The addition of KinetiSol Technology strengthens our advanced oral drug delivery capabilities and provides customers with greater flexibility as they move innovative therapies from IND approval to commercialisation.
"This collaboration reflects our shared commitment to enabling solutions for challenging molecules and improving access to critical treatments for patients worldwide."
